Abstract
This review explores the salient issues surrounding liver injury and liver monitoring associated with beta-interferon (IFNB) treatment for multiple sclerosis (MS). Post-marketing studies have found a higher proportion of IFNB-treated MS patients with elevated aminotransferases than reported in the pivotal clinical trials. Although the risk of severe liver injury appears small, the true incidence is unknown. Post-marketing studies have shown that the greatest period of risk for the development of liver test abnormalities appears to be in the first year of IFNB treatment. The risk also increases with the more frequently administered, higher-dosage IFNBs. Males are more likely than females to develop elevated aminotransferases (> upper normal limit), although females appear at a greater risk of severe liver injury. Of the commonly used biochemical liver tests, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP) and bilirubin appear the most useful for routine monitoring of IFNB treatment. Whilst many other factors can affect liver test results, including obesity, alcohol, concomitant medications, co-morbidities and theoretically even MS itself, regular liver testing both prior and during IFNB therapy might help minimise Type A or dose/frequency dependent aminotransferase elevations. However, testing will probably not prevent the Type B idiosyncratic reactions which can result in severe hepatic injury; hence patients need to be aware, and to report hepatic side effects promptly.
Similar content being viewed by others
References
Ferguson J, Sandrock A (2003) Important New Prescribing Information. http://www.fda.gov/medwatch/SAFET Y/2003/avonex_deardoc.pdf (Accessed 16 Dec 2003)
Gehshan A, Ruebig A, Salesse M (2003) Important new safety information: Hepatic injury associated with beta-interferon treatment for Multiple Sclerosis http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/beta-interferon_hpc_e.pdf (Accessed 16 Dec 2003)
CDER-PHRMA-AASLD (2000) Drug-induced hepatotoxicity White Paper Postmarketing Considerations. http:www//fda.gov/cder/livertox/postmarket.pdf (Accessed 28 July 2003)
Lewis JA (1981) Post-marketing surveillance—how many patients? Trends Pharmacol Sci 2:93–94
Rawlins MD (1988) Spontaneous reporting of adverse drug reactions I: The data. Br J Clin Pharmacol 26:1–5
Zakim D, Boyer T (1996) Hepatology: A textbook of liver disease (London, Saunders)
CDER-PHRMA-AASLD (2000) Drug-induced Hepatotoxicity. Clinical White Paper. http:www//fda.gov/cder/livertox/clinical.pdf (Accessed July 28th 2003)
Kaplan MM (2002) Alanine aminotransferase levels: what’s normal? Ann Intern Med 137:49–51
Pratt DS, Kaplan MM (2000) Evaluation of Abnormal Liver-Enzyme Results in Asymptomatic Patients. N Engl J Med 342:1266–1271
Kew M (2000) Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 355:591–592
Dufour DR (2000) Laboratory guidelines for screening, diagnosis and monitoring of hepatic injury. Washington, D. C., USA: National Academy of Clinical Biochemistry
Minuk GY (1998) Canadian Association of Gastroenterology Practice Guidelines: Evaluation of abnormal liver enzyme tests. Can J Gastroenterol 12:417–421
Crispe I (1999) T lymphocytes in the Liver. Wiley-Liss, New York
Dobin NB, Switzer JL (1954) Liver function and other blood chemistry tests in multiple sclerosis. AMA Arch Neurol Psych 71:405–424
Kojima H, Uemura M, Sakurai S, Ann T, Ishii Y, Imazu H, Yoshikawa M, Ichijima K, Fukui H (2002) Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance. J Gastroenterol 37:617–625
Thompson P Jr, Strum D, Boehm T, Wartofsky L (1978) Abnormalities of liver function tests in tyrotoxicosis. Mil Med 143:548–551
Nunez-Martinez O, Alvarez E, Clemente G, Rodriguez-Mahuo M, de Andres C (2003) Autoimmune hepatitis and multiple sclerosis P161. Mult Scler 9:S34–S35
Pontecorvo MJ, Levinson JD, Roth JA (1992) A patient with primary biliary cirrhosis and multiple sclerosis. Am J Med 92:433–436
Prahalad S, Shear ES, Thompson SD, Giannini EH, Glass DN (2002) Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis Rheum 46:1851–1856
Sadovnick AD, Paty DW (1989) Concurrence of Multiple Sclerosis and Inflammatory bowel disease. N Engl J Med 321:762–763
Renton KW (2001) Alterations of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147–163
Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van Der Meche FG, van Doorn PA, Hintzen RQ (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125:952–960
Stricker B (1992) Drug-Induced Hepatic Injury, 2nd edn. Elsevier, Amsterdam
Tremlett HL, Wiles CM, Luscombe DK (2001) Prescribing for MS patients in General Practice: a case control study. J Clin Pharm Ther 26:437–444
Larrey D (2000) Drug-induced liver diseases. J Hepatol 32:77–88
Sterling MJ, Kane M, Grace ND (1996) Pemoline-induced autoimmune hepatitis. Am J Gastroenterol 91:2233–2234
Chan CH (1990) Dantrolene sodium and hepatic injury. Neurology 40:1427–1432
Lapierre Y, Bouchard S, Tansey C, Gendron D, Barkas WJ, Francis GS (1987) Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci 14:513–517
Schattner A, Von der Walde J, Kozak N, Sokolovskaya N, Knobler H (1999) Nitrofurantoin-induced immune-mediated lung and liver disease. Am J Med Sci 317:336–340
Mion F, Napoleon B, Berger F, Chevallier M, Bonvoisin S, Descos L (1991) Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 32:715–717
Davies DM, Cavanagh J (1967) Jaundice from potassium p-aminobenzoate. Lancet 1:896
Luparini R, Rotundo A, Mattace R, Marigliano V (2000) Possibly ranitidine-induced autoimmune hepatitis. Ann Ital Med Int 15:214–217
Hullar TE, Sapers BL, Ridker PM, Jenkins RL, Huth TS, Farraye FA (1999) Herbal toxicity and fatal hepatic failure. Am J Med 106:267–268
Hollifield RD, Harbige LS, Pham-Dinh D, Sharief MK (2003) Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity 36:133–141
Durelli L, Bongioanni MR, Ferrero B, Oggero A, Marzano A, Rizzetto M (1998) Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 50:570–571
Yoshida EM, Rasmussen SL, Steinbrecher UP, Erb SR, Scudamore CH, Chung SW, Oger JJ, Hashimoto SA (2001) Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 56:1416
Francis GS, Grumser Y, Alteri E, Micaleff A, O’Brien F, Alsop J, Moraga MS, Kaplowitz N (2003) Hepatic Reactions during treatment of Multiple Sclerosis with Interferon-beta-1a. Drug Safety 26:815–827
Duchini A (2002) Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Am J Gastroenterol 97:767–768
Jacobs LD, The Multiple Sclerosis Collaborative Research Group (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–15041
Tremlett H, Yoshida EM, Oger J (2004) Liver injury associated with the Beta-Interferons for MS: a comparison between the three products. Neurology 62:628–63
Benichou C, CIOMS (1990) Criteria of drug-induced liver disorders. J Hepatol 11:272–276
Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169–178
Nosaka K, Sakamoto K (1999) Changes in plasma enzyme activity after intramuscular injection of bupivacaine into the human biceps brachii. Acta Physiol Scand 167:259–265
Perry MC (1992) Chemotherapeutic agents and heptotoxicity. Sem Oncol 19:551–565
Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW (1993) Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplasic syndromes. Am J Clin Oncol 16:159–163
Fujimore K, Mochida S, Matsui A, Ohno A, Fujiwara K (2002) Possible mechanisms of elevation of serum transaminase levels during interferonbeta therapy in chronic hepatitis C patients. J Gastroenterol 37:40–46
Kellokumpu-Lehtinen P, Iisalo E, Nordman E (1989) Hepatotoxicity of paracetamol in combination with interferon and vinblastine. Lancet 1:1143
Fabris P, Palma MD, de Lalla F (2001) Idiosyncratic acute hepatitis caused by paracetamol in two patients with melanoma treated with high-dose interferon-alpha. Ann Intern Med 134:345
Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dahlke F, Gasperini C (2002) Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 249:50–56
Lee WM (2003) Drug-induced Hepatotoxicity. N Engl J Med 349:474–485
Sena A, Pedrosa R, Ferret-Sena V, Almeida R, Andrade ML, Morais MG, Couderc R (2000) Interferon beta1a therapy changes lipoprotein metabolism in patients with multiple sclerosis. Clin Chem Lab Med 38:209–213
Schectman G, Kaul S, Mueller RA, Borden EC, Kissebah AH (1992) The effect of interferon on the metabolism of LDLs. Arterioscler Thromb 12:1053–1062
Rosenzweig IB, Wiebe DA, Borden EC, Storer B, Shrago ES (1987) Plasma lipoprotein changes in humans induced by beta-interferon. Atherosclerosis 67:261–267
Amacher DE (1998) Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol 27:119–130
Anonymous (2003) Common Terminology Criteria for Adverse Events, National Cancer Institute. Cancer Therapy Evaluation Program. http://ctep.cancer.gov/reporting/ctc.html (Accessed 10 July, 2003)
Wang CS, Wang ST, Chang TT, Yao WJ, Chou P (2002) Smoking and Alanine Aminotransferase Levels in Hepatitis C Virus Infection. Arch Intern Med 162:811–815
The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661
Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E, Zaffaroni M (2001) Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Neurology 57:1363–1370
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tremlett, H., Oger, J. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol 251, 1297–1303 (2004). https://doi.org/10.1007/s00415-004-0619-5
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00415-004-0619-5